Seqens Creditors Tap Paul Weiss as Cash Hits ‘Critical Point’

Creditors holding €930 million ($1.1 billion) in term loans for French pharmaceuticals firm Seqens SASU have engaged Paul Weiss Rifkind Wharton & Garrison as legal counsel amid growing concerns over the company's liquidity. This action follows S&P Global Ratings' recent downgrade of Seqens to CCC, citing that its cash position has reached a 'critical point'.

Analysis

Seqens SASU is facing a severe liquidity crisis, evidenced by the retention of legal adviser Paul Weiss by a group of its creditors. This move by holders of the €930 million term loan due 2028 indicates a preparation for potential debt restructuring or default proceedings. The situation is further validated by S&P Global Ratings' recent downgrade of the French pharmaceutical firm to CCC, a rating that signifies a high risk of nonpayment. S&P's specific warning that the company's liquidity has reached a "critical point" underscores the imminence of the financial distress. The article notes these financial troubles have been accumulating for some time, suggesting a sustained deterioration of the company's fundamentals rather than a sudden, unexpected event.

Key Decisions for Investors

• Investors holding the Seqens term loan should actively engage with the creditor group and its legal counsel to prepare for restructuring negotiations and protect their position, as a CCC rating implies a default is a real possibility.
• This event serves as a significant red flag for private credit investors, highlighting the need for heightened due diligence on the liquidity and cash flow resilience of other highly leveraged portfolio companies, particularly within the capital-intensive pharmaceutical sector.
• Monitor the broader private credit market for signs of stress, as the issues at Seqens could be indicative of wider problems among companies with similar leverage profiles facing operational or refinancing pressures.